Go Pro

Aptevo Therapeutics (APVO) Earnings Date, Estimates & Call Transcripts

Aptevo Therapeutics logo
$2.94 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$2.99 +0.05 (+1.67%)
As of 08/14/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aptevo Therapeutics Earnings Summary

Aptevo Therapeutics announced Q2 2026 earnings on August 14, 2026, reporting an EPS of -$5.31, which topped the consensus estimate of -$6.02 by $0.71. With a trailing EPS of -$197.60, Aptevo Therapeutics' earnings are expected to grow next year, from ($23.35) to ($12.12) per share.

Q2 2026 Earnings Resources

APVO Upcoming Earnings

Aptevo Therapeutics' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Upcoming Q3
Earnings Date
Nov. 5Before Market OpensEstimated
Consensus EPS
(Aug. 14)
-$6.02
Actual EPS
(Aug. 14)
-$5.31 Beat By $0.71
Get Aptevo Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptevo Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

APVO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Aptevo Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20261-$5.83-$5.83-$5.83
Q3 20261-$5.38-$5.38-$5.38
Q4 20261-$5.14-$5.14-$5.14

Aptevo Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/5/2026
(Estimated)
--------
8/14/2026Q2 2026-$6.0150-$5.31+$0.7050-$5.31--
5/13/2026Q1 2026-$6.41-$6.41--$6.41--
3/26/2026Q4 2025-$8.10$118.23+$126.33$118.23--
11/6/2025Q3 2025-$37.62-$40.14 -$2.52-$2.23--
8/11/2025Q2 2025-$1,497.60-$151.20+$1,346.40-$8.40--
5/15/2025Q1 2025-$1,515.60-$1,580.40 -$64.80-$4.39--

Aptevo Therapeutics Earnings - Frequently Asked Questions

Aptevo Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 5th, 2026 based off last year's report dates. Learn more on APVO's earnings history.

In the previous quarter, Aptevo Therapeutics (NASDAQ:APVO) reported ($5.31) earnings per share (EPS) to beat the analysts' consensus estimate of ($6.02) by $0.71. Learn more on analysts' earnings estimate vs. APVO's actual earnings.

Aptevo Therapeutics (NASDAQ:APVO) has a recorded net income of -$25.97 million. APVO has generated -$197.60 earnings per share over the last four quarters.

Aptevo Therapeutics' earnings are expected to grow from ($23.35) per share to ($12.12) per share in the next year.


Earnings data for NASDAQ:APVO is sourced from Fiscal.ai, with the most recent quarter reported on 8/14/2026. New results are added as companies report their earnings.
From Our Partners